American Journal of Epidemiology Vol. 153, No. 10 : 961-968
Copyright © 2001 by The Johns Hopkins University School of Hygiene and Public Health
ORIGINAL CONTRIBUTIONS |
Neural Tube Defects in Relation to Use of Folic Acid Antagonists during Pregnancy
1 Slone Epidemiology Unit, Boston University School of Public Health, Brookline, MA.
2 Department of Epidemiology, Harvard School of Public Health, Boston, MA.
Periconceptional folic acid supplementation reduces the risk of neural tube defects (NTDs). To determine whether periconceptional exposure to folic acid antagonists (FAAs) might therefore increase the risk of NTDs, the authors examined data from an ongoing case-control study of birth defects (1979–1998) in the United States and Canada. They compared data on 1,242 infants with NTDs (spina bifida, anencephaly, and encephalocele) with data from a control group of 6,660 infants with malformations not related to vitamin supplementation. Mothers were interviewed within 6 months of delivery about demographic, reproductive, medical, and behavioral factors and about medication use. The adjusted odds ratios of NTDs related to exposure to FAAs (including carbamazepine, phenobarbital, phenytoin, primidone, sulfasalazine, triamterene, and trimethoprim) during the first or second months after the last menstrual period, compared with no use in either month, were 2.8 (95% confidence interval: 1.7, 4.6) for FAAs as a group, 4.8 (95% confidence interval: 1.5, 16.1) for trimethoprim (based on five exposed cases), and 6.9 (95% confidence interval: 1.9, 25.7) for carbamazepine (six exposed cases). These results are adjusted for region, interview year, periconceptional folic acid supplementation, maternal age, weight, education, and infections early in pregnancy. These findings suggest that a number of FAAs may increase NTD risk, and they provide estimates of risk for selected drugs.
carbamazepine; case-control studies; folic acid antagonists; neural tube defects; pregnancy; teratogens; trimethoprim
Abbreviations: CI, confidence interval; FAA, folic acid antagonist; NTD, neural tube defect.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. S. Crider, M. A. Cleves, J. Reefhuis, R. J. Berry, C. A. Hobbs, and D. J. Hu Antibacterial Medication Use During Pregnancy and Risk of Birth Defects: National Birth Defects Prevention Study Arch Pediatr Adolesc Med, November 1, 2009; 163(11): 978 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J I Morrow, S J Hunt, A J Russell, W H Smithson, L Parsons, I Robertson, R Waddell, B Irwin, P J Morrison, and J J Craig Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register J. Neurol. Neurosurg. Psychiatry, May 1, 2009; 80(5): 506 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Wen MB PhD, J. Zhou MB MSc, Q. Yang MD PhD, W. Fraser MD MSc, O. Olatunbosun MD, and M. Walker MSc MD Maternal exposure to folic acid antagonists and placenta-mediated adverse pregnancy outcomes Can. Med. Assoc. J., December 2, 2008; 179(12): 1263 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Holmes, E. J. Baldwin, C. R. Smith, E. Habecker, L. Glassman, S. L. Wong, and D. F. Wyszynski Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy Neurology, May 27, 2008; 70(22_Part_2): 2152 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang, S. L. Carmichael, M. Canfield, J. Song, G. M. Shaw, and the National Birth Defects Prevention Study Socioeconomic Status in Relation to Selected Birth Defects in a Large Multicentered US Case-Control Study Am. J. Epidemiol., January 15, 2008; 167(2): 145 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chambers, G. Koren, Z. N. Tutuncu, D. Johnson, and K. L. Jones Are new agents used to treat rheumatoid arthritis safe to take during pregnancy?: Organization of Teratology Information Specialists (OTIS) study Can Fam Physician, March 1, 2007; 53(3): 409 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Kaplan Reproductive health effects and teratogenicity of antiepileptic drugs Neurology, November 23, 2004; 63(10_suppl_4): S13 - S23. [Abstract] [Full Text]
|
|
|
|
|
|
P. B. Pennell The importance of monotherapy in pregnancy Neurology, June 10, 2003; 60(90114): S31 - 38. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Zetterberg, B. Regland, M. Palmer, L. Rymo, A. Zafiropoulos, D.A. Arvanitis, D.A. Spandidos, and K. Blennow The transcobalamin codon 259 polymorphism influences the risk of human spontaneous abortion Hum. Reprod., December 1, 2002; 17(12): 3033 - 3036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Polifka and J.M. Friedman Medical genetics: 1. Clinical teratology in the age of genomics Can. Med. Assoc. J., August 1, 2002; 167(3): 265 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Green Folic Acid Supplementation and Prevention of Birth Defects J. Nutr., August 1, 2002; 132(8): 2356S - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Eskild and P. Magnus Commentary: Little evidence of effective prenatal treatment against congenital toxoplasmosis--the implications for testing in pregnancy Int. J. Epidemiol., December 1, 2001; 30(6): 1314 - 1315. [Full Text] [PDF]
|
|
|
|
 |
|
 Folic-Acid Antagonists Are Associated with Neural-Tube Defects Journal Watch Women's Health, August 14, 2001; 2001(814): 1 - 1. [Full Text]
|
|